Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
Status:
Completed
Trial end date:
2019-10-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of pimavanserin compared to placebo in
preventing relapse of psychotic symptoms in subjects with dementia-related psychosis who
responded to 12 weeks of open label pimavanserin treatment.